MetaCap

MAIA Biotechnology Inc. (MAIA)

NYSE: MAIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.11-0.03 (-2.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MAIA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$68.54M
EPS (TTM)
-$0.47
52-week range
0.895 – 3.19
Day range
1.08 – 1.15
Volume / Avg
498.73K / 524.29K
Beta
—

52-week range

$0.895$3.19

MAIA stock today

On Nov 20, MAIA ended the session at $1.11, shedding $0.03 (2.63%), versus the S&P 500's 3.70% decline. At this level, MAIA sits near the bottom of its 52-week range of $0.895 to $3.19: 65.2% below the high, set on Jan 28, 2026 and 24.0% above the low. MAIA is down 27.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.7%.

MAIA Biotechnology has posted a net loss over the last twelve months (EPS of -$0.47), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MAIA Biotechnology

Company profile

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Vlad Vitoc M.B.A., M.D.
Headquarters
Chicago, IL
Employees
13
IPO year
2022

Financial highlights

Full financials

MAIA Biotechnology reported a net loss of $22.4 million, compared with a loss of $23.3 million a year earlier. Diluted earnings per share came in at -$0.70.

MAIA Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$0$0$0—
Growth—————
Net income$-22.40M$-23.25M$-19.77M$-15.77M$-12.58M
EPS (diluted)$-0.70$-1.05$-1.49$-1.75$-2.37

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$12.00+981.08%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.12 vs $-0.13
Surprise
+7.69%

MAIA news

All MAIA news

MAIA Biotechnology peers

Health Care sector
MAIA peer companies
CompanyPrice% ChgMarket capCompare
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs MAIA
CINGCingulate Inc.4.51-14.26%$67.48Mvs MAIA
MNOVMedicinova Inc1.31+3.15%$67.11Mvs MAIA
ZYBTZhengye Biotechnology Holding Limited Class A1.48-2.63%$70.14Mvs MAIA
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs MAIA
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs MAIA
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs MAIA
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs MAIA

Indexes, lists and sector

MAIA Biotechnology stock FAQ

What is MAIA Biotechnology's stock price today?

MAIA last traded at $1.11 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.

Who is MAIA Biotechnology's CEO?

Dr. Vlad Vitoc M.B.A., M.D. is the chief executive officer of MAIA Biotechnology Inc., which has about 13 employees.

What is the MAIA 52-week high?

The 52-week high for MAIA is $3.19 and the 52-week low is $0.895. The stock is currently 65.2% below its high.

Compare MAIA